Biochemicals and Reagents

Nemiralisib is a small molecule that inhibits the PD-L1 protein. It can be used to treat cancer and autoimmune diseases. Nemiralisib binds to the PD-L1 protein and prevents it from binding to its ligands, CD80 or CD86. This prevents the immune system from being suppressed by the PD-L1 protein and may enable an anti-PD-L1 therapy to induce tumor regression in patients with cancer. Nemiralisib has been shown to inhibit P-glycoprotein (Pgp) activity in vitro, which may result in drug interactions with other drugs that are substrates of this transporter. Nemiralisib has a terminal half life of approximately 6 hours, meaning that most of it will be eliminated from the body within 24 hours after administration. The chemical name for nemiralisib is 1-[3-(4-chlorophenyl)phenyl]-3-[2-(methylsulfonyl)phenyl]urea. The

CD40 antibody (biotin) was raised in rat using CD40 as the immunogen

GW 542573X is a synthetic compound that binds to the cytochrome P450 protein and inhibits its activity. This drug has been shown to activate cellular potassium ion channels, which leads to an increase in intracellular calcium levels by activating voltage-gated calcium channels. This causes cancer cell death and can be used as a potential therapeutic agent for cancer treatment. GW 542573X is also an antagonist of calmodulin that binds to this protein with high affinity, but does not inhibit its biological function.

Velaresol is a small molecule drug that binds to the CB2 receptor. It has been shown to have therapeutic potential in treating bowel diseases, such as inflammatory bowel disease and irritable bowel syndrome, as well as autoimmune diseases such as multiple sclerosis and type 1 diabetes. Velaresol has also been shown to be effective against cancer cells in vitro and in vivo, with a mechanism of action that is not yet understood. The drug also inhibits the production of proinflammatory cytokines and ameliorates inflammation by binding to toll-like receptors on immune cells. Velaresol has been synthesized using a biocompatible polymer, which may make it suitable for use in diagnostic applications.

BTUM is a medicinal compound that acts as an analog of human kinases. It has been shown to have potent anticancer properties, inhibiting the growth and proliferation of cancer cells by inducing apoptosis and disrupting the cell cycle. BTUM works by binding to specific proteins in cancer cells, which are involved in the regulation of cell growth and division. This inhibitor prevents these proteins from functioning properly, leading to the suppression of tumor growth. BTUM has been extensively studied in Chinese medicine, where it has been used for its anti-cancer properties for many years. With its ability to target cancer cells specifically, BTUM is a promising candidate for the development of new cancer therapies.

Please enquire for more information about A-887826-d8 including the price, delivery time and more detailed product information at the technical inquiry form on this page

Auristatin F TFA salt is a potent antitumor agent that can be used for the treatment of solid tumours. It inhibits the growth of cancer cells by binding to epidermal growth factor (EGF) receptors and blocking the action of EGF. Auristatin F TFA salt has been shown to induce apoptosis in prostate cancer cells and can also act as a potential biomarker for tumour response. The drug is not toxic to healthy cells, but it is rapidly eliminated from the body due to its short half-life. Auristatin F TFA salt has been shown to have pharmacokinetic properties that are similar in mice, rats, and humans. This drug also binds monoclonal antibodies against EGFR, which may serve as an alternative treatment for cancer patients who develop resistance to temozolomide.